Intravenous immunoglobulins for multiple sclerosis (Q24247968)

Cochrane Database of Systematic Reviews

Europe PubMed Central

title

Intravenous immunoglobulins for multiple sclerosis (English)

0 references

0 references

Orla Gray

1

0 references

Gavin V McDonnell

series ordinal

2

0 references

Raeburn B Forbes

series ordinal

3

0 references

publication date

21 July 2003

0 references

published in

0 references

cites work

Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

IV immunoglobulin does not reverse established weakness in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Complications of intravenous immune globulin treatment in neurologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

More immunotherapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Safety of intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

Immunoglobulins promote remyelination in the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

Remyelination by oligodendrocytes stimulated by antiserum to spinal cord

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD002936

7 January 2021

10.1002/14651858.CD002936

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6uu2r66zl5hyzpxfm5uhjzmdpq

30 July 2022

mapped directly with Wikidata item

Fatcat ID

release_6uu2r66zl5hyzpxfm5uhjzmdpq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6uu2r66zl5hyzpxfm5uhjzmdpq

30 July 2022

mapped directly with Wikidata item

PubMed publication ID

1 reference

https://api.fatcat.wiki/v0/release/6uu2r66zl5hyzpxfm5uhjzmdpq

30 July 2022